Inclusion Criteria:  Biopsy-confirmed diagnosis of squamous cell carcinoma of the head and neck Subjects newly diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Subjects are to be staged clinically and radiographically node negative (cN0) Planned standard of care surgery with curative intent for squamous cell carcinoma Age > 18 years  Have acceptable hematologic status, coagulation status (11 to 13.5 seconds. international normalized ratio (INR) of 0.8 to 1.1), kidney function, and liver function including the following clinical results:  Hemoglobin ≥ 9 gm/dL White blood cell count ≥ 3000/mm3 Platelet count ≥ 100,000/mm3 Serum creatinine ≤ 1.5 times upper reference range alanine transaminase (ALT) (SGPT) 7-56 units/liter, aspartate aminotransferase (AST) (SGOT) 5-40 units/liter.  Exclusion Criteria:  Received an investigational drug within 30 days prior to the first dose of [89Zr]panitumumab. Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment. Previous HNSCC resection. History of infusion reactions to monoclonal antibody therapies. Pregnant or breast-feeding women. Magnesium (<1.7 mg/dL) or potassium (<3.6 mmol/L) lower than the normal institutional values. Subjects receiving Class I-A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis. Severe renal disease or anuria (Creatinine within normal institutional limits OR Creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels). Known hypersensitivity to panitumumab or any of its components. Weight over 350 lbs., due to the scanner bore size. Contraindication for MRI procedures (e.g. non-removable metal implants or certain tattoos).